Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Toripalimab + Oxaliplatin + Tegafur + Gimeracil + Oteracil Potassium
- Development stage
- Phase 2
- Lead developer
- Junshi Biosciences
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination therapy regimen combining an immunotherapy agent (toripalimab) with chemotherapy components (oxaliplatin, tegafur, gimeracil, and oteracil potassium), primarily used for gastric cancer treatment. Toripalimab is a humanized anti-PD-1 monoclonal antibody that blocks the PD-1 pathway to prevent immune evasion by cancer cells. Oxaliplatin is a third-generation platinum drug commonly used in combination for various cancers. Tegafur + Gimeracil + Oteracil Potassium (TGOP), also known as Teggio or part of S-1/SOX regimens, consists of tegafur (a 5-fluorouracil prodrug), gimeracil (a dihydropyrimidine dehydrogenase inhibitor), and oteracil potassium (a gastrointestinal mucosal protective agent). This combination represents an approach integrating immune checkpoint inhibition with chemotherapy to enhance anti-tumor effects.
- Brand names
- Tuoyi
- Other names
- Tripletrumab Combined With Oxaliplatin and Teggio (SOX)Toripalimab + SOX
02
Targets
DNADPYD (Dihydropyrimidine dehydrogenase)OPRT (Orotidine 5'-phosphate decarboxylase)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on Toripalimab + Oxaliplatin + Tegafur + Gimeracil + Oteracil Potassium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Toripalimab + Oxaliplatin + Tegafur + Gimeracil + Oteracil Potassium.